Gabriel Figueroa-Parra, Molly M Jeffery, Jesse Y Dabit, Baptiste Chevet, Maria O Valenzuela-Almada, Mehmet Hocaoglu, Shirley-Ann Osei-Onomah, Shaheen Kurani, Sebastian Vallejo, Sara J Achenbach, W Michael Hooten, Kamil E Barbour, Cynthia S Crowson, Alí Duarte-García
OBJECTIVE: There is little information about the epidemiology and factors associated with opioid therapy in systemic lupus erythematosus (SLE). We aimed to assess the prevalence of opioid therapy and explore factors associated with long-term opioid therapy (LTOT) in patients with SLE. METHODS: Patients with SLE were matched with non-SLE controls in a population-based cohort on January 1, 2015. We captured demographics, manifestations of lupus, comorbidities (fibromyalgia, mood disorders, osteoarthritis, chronic low back pain [CLBP], chronic kidney disease, avascular necrosis, osteoporosis, fragility fractures, and cancer), and the area deprivation index (ADI)...
November 15, 2022: Journal of Rheumatology